Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,390 matching trials from the live ClinicalTrials.gov search.
Conditions
Influenza, Human
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
44
States / cities
Chandler, Arizona • Costa Mesa, California • Garden Grove, California + 37 more
Conditions
Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
Interventions
AZD8853, Zirconium-89 crefmirlimab berdoxam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri • Providence, Rhode Island + 1 more
Active, not recruiting Not applicable Interventional Results available

Electrical Nerve Block for Amputation Pain

NCT02221934
Conditions
Post-Amputation Pain, Phantom Limb Pain, Residual Limb Pain, Stump Pain
Interventions
Altius
Device
Lead sponsor
Neuros Medical, Inc.
Industry
Eligibility
21 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
22
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Denver, Colorado + 18 more
Recruiting Not applicable Interventional

Home Hospital for Suddenly Ill Adults

NCT03524222
Conditions
Infection, Heart Failure, COPD, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Home Hospitalization
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Otitis Media, Urinary Tract Infection, Asthma, Head Injury
Interventions
patient-driven health IT product
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 12 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts • Weymouth, Massachusetts
Conditions
Ovarian, Melanoma, Renal, Prostate, Colorectal, Endometrial Carcinoma, Cervical Carcinoma, Testicular Cancer, Thyroid Cancer, Small Cell Lung Carcinoma, Mesothelioma, Breast Carcinoma, Esophageal Carcinoma, Gastric Cancer, Pancreatic Carcinoma, Neuroendocrine Cancer, Liver Cancer, Gallbladder Cancer, Biliary Tract Cancer, Anal Carcinoma, Bone Sarcomas, Soft Tissue Sarcomas, Carcinoma of Unknown Origin, Primary
Interventions
PSMA/PRAME
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
5
States / cities
Tuscon, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 2 more
Conditions
Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer
Interventions
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 17 more
Conditions
Renal Cell Carcinoma, Melanoma, Lung Cancer
Interventions
Infliximab + Prednisone, Methylprednisolone + Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more
Conditions
Breast Cancer, Lung Cancer, Ovarian Cancer
Interventions
HER-2/neu peptide vaccine, sargramostim
Biological
Lead sponsor
University of Washington
Other
Eligibility
Up to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sex Steroids, Sleep, and Metabolic Dysfunction in Women

NCT00805207
Conditions
Polycystic Ovary Syndrome (PCOS), Obstructive Sleep Apnea, Obesity
Interventions
Progesterone, testosterone, glucocorticoid, continuous positive airway pressure, Estrogen, Control
Drug · Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Recruiting No phase listed Observational Accepts healthy volunteers

Direct to Patient Minimal Risk Biospecimen and Data Collection Research

NCT07128966
Conditions
Healthy, Lupus, Celiac, Kidney Disease, Chronic, Dermatologic
Interventions
Observation
Other
Lead sponsor
Joined Bio
Industry
Eligibility
18 Years to 90 Years
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2036
U.S. locations
1
States / cities
Lexington, Massachusetts
Conditions
Atelectasis
Interventions
Incentive Spirometry, EzPAP® Positive Airway Pressure
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 79 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Melanoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer
Interventions
HBI-8000 in combination with nivolumab
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Phoenix, Arizona • La Jolla, California • Port Saint Lucie, Florida + 3 more
Conditions
Adult Solid Tumor
Interventions
CANscript
Diagnostic Test
Lead sponsor
Mitra RxDx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Timeline
2017 – 2019
U.S. locations
30
States / cities
Gilbert, Arizona • Aurora, Colorado • Norwich, Connecticut + 23 more
Conditions
Respiratory Complication
Interventions
Focused incentive spirometer education and monitoring
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Terminated No phase listed Observational Accepts healthy volunteers

Pilot Study of Model Based Iterative Reconstruction Using 64-Slice

NCT01431378
Conditions
Posterior Fossa Hemorrhage, Lung Cancer, Flank Pain, Urolithiasis, Focal Hepatic Necrosis
Interventions
Not listed
Lead sponsor
GE Healthcare
Industry
Eligibility
30 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina • Miwaukee, Wisconsin
Conditions
Neoplasms
Interventions
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
Conditions
Advanced Cancer
Interventions
Avelumab, Utomilumab, PF-04518600, PD 0360324, CMP-001
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
57
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 23 more
Completed Not applicable Interventional Results available

Facilitating Communication Study

NCT03721952
Conditions
Chronic Disease, Neoplasm Metastasis, Lung Neoplasm, Pulmonary Disease, Chronic Obstructive, Heart Failure, Congestive, Liver Cirrhosis, Kidney Failure, Chronic, Multiple Organ Failure, Health Care Quality, Access, and Evaluation, Intensive Care Units, Palliative Care, Health Services, Palliative Care, Patient Care, Lung Diseases, Cerebrovascular Disorders, Brain Injuries
Interventions
Facilitator-Based Intervention
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
977 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Seattle, Washington
Conditions
Bladder Cancer, Gastric Cancer, Non Small Cell Lung Cancer, NSCLC, Urothelial Carcinoma, Advanced Solid Tumor
Interventions
APR-246 (eprenetapopt) + Pembrolizumab
Drug
Lead sponsor
Aprea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more
Conditions
Renal Cell Carcinoma, Lung Carcinoma, Cervical Carcinoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
Interventions
XmAb®808, Keytruda® (pembrolizumab)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Sarasota, Florida + 9 more
Conditions
Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
PF-08046876, Pembrolizumab, Cisplatin, Carboplatin
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
21
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 11 more
Conditions
Breast Cancer Related Lymphedema, Covid19
Interventions
Survey
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts